Literature DB >> 9143358

The human glycinamide ribonucleotide transformylase domain: purification, characterization, and kinetic mechanism.

C A Caperelli1, E L Giroux.   

Abstract

Glycinamide ribonucleotide transformylase catalyzes the third reaction of de novo purine biosynthesis, namely, the conversion of glycinamide ribonucleotide to N-formylglycinamide ribonucleotide, with concomitant conversion of 10-formyltetrahydrofolate to tetrahydrofolate. This activity has been shown to be a target for cancer chemotherapy, which has generated renewed interest in both the enzyme and the pathway. Moreover, in higher eukaryotes this activity constitutes the C-terminal domain of a monomeric protein which also catalyzes two additional reactions of de novo purine biosynthesis. In this study, the human glycinamide ribonucleotide transformylase domain has been expressed to high levels in Escherichia coli and purified to homogeneity. Our improved expression-purification system produces the desired activity exclusively in a soluble form and in higher abundance than previously achieved. The kinetic constants have been determined and the kinetic mechanism has been established as ordered-sequential, with the folate substrate binding first. The correspondence of these data to those obtained for the glycinamide ribonucleotide transformylase activity of the mammalian trifunctional enzyme indicates that the recombinant enzyme is fully functional.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143358     DOI: 10.1006/abbi.1997.9947

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

1.  6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.

Authors:  Lei Wang; Adrianne Wallace; Sudhir Raghavan; Siobhan M Deis; Mike R Wilson; Si Yang; Lisa Polin; Kathryn White; Juiwanna Kushner; Steven Orr; Christina George; Carrie O'Connor; Zhanjun Hou; Shermaine Mitchell-Ryan; Charles E Dann; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2015-08-28       Impact factor: 7.446

2.  Human glycinamide ribonucleotide transformylase: active site mutants as mechanistic probes.

Authors:  Wanda Manieri; Molly E Moore; Matthew B Soellner; Pearl Tsang; Carol A Caperelli
Journal:  Biochemistry       Date:  2007-01-09       Impact factor: 3.162

Review 3.  Novel antifolate drugs.

Authors:  W Thomas Purcell; David S Ettinger
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

4.  Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Lalit K Golani; Adrianne Wallace-Povirk; Siobhan M Deis; Jennifer Wong; Jiyuan Ke; Xin Gu; Sudhir Raghavan; Mike R Wilson; Xinxin Li; Lisa Polin; Parker W de Waal; Kathryn White; Juiwanna Kushner; Carrie O'Connor; Zhanjun Hou; H Eric Xu; Karsten Melcher; Charles E Dann; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2016-08-26       Impact factor: 7.446

5.  Protein preparation, crystallization and preliminary crystallographic studies of Bacillus subtilis glycinamide ribonucleotide transformylase.

Authors:  Yu-He Liang; Xiang-Yu Liu; Juan Wang; Lan-Fen Li
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27

6.  Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.

Authors:  Siobhan M Deis; Arpit Doshi; Zhanjun Hou; Larry H Matherly; Aleem Gangjee; Charles E Dann
Journal:  Biochemistry       Date:  2016-08-03       Impact factor: 3.162

7.  Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate.

Authors:  Jiahong Xiang; Mengqi Wu; Jianchao Wang; Mengmeng Lin; Mengmeng Sun; Xin Li; Ruijuan Xing; Ran Guo; Jianmin Gu; Tao Lyu; Lei Wang; Xiaowei Shi
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.